{
    "name": "atezolizumab",
    "comment": "Rx",
    "other_names": [
        "Tecentriq"
    ],
    "classes": [
        "PD-1/PD-L1 Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/tecentriq-atezolizumab-1000098",
    "pregnancy": {
        "common": [
            "Based on its mechanism of action, can cause fetal harm when administered during pregnancy",
            "No available data on use in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus, resulting in fetal death"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Advise females of reproductive potential to use effective contraception during treatment and for at least 5 months following the last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on animal studies, atezolizumab may impair fertility in females of reproductive potential while receiving treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "As human IgG is excreted in human milk, potential for absorption and harm to the infant is unknown",
            "Advise lactating woman not to breastfeed during treatment and for at least 5 months after the last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Immune-mediated pneumonitis or interstitial lung disease occurred; monitor for signs and symptoms of pneumonitis; incidence of pneumonitis is higher in patient who have received thoracic radiation",
                "May cause liver test abnormalities and immune-mediated hepatitis; fatal cases reported; monitor for signs and symptoms of hepatitis, during and after discontinuation of therapy, including clinical chemistry monitoring",
                "Immune-mediated colitis or diarrhea reported",
                "May cause severe or life-threatening infusion-related reactions; monitor for signs and symptoms of infusion-related reactions",
                "Severe infections (eg, sepsis, herpes encephalitis, mycobacterial infection) leading to retroperitoneal hemorrhage reported; most common infection was upper respiratory tract infection; monitor for signs and symptoms of infection",
                "Hematologic/immune effects may include hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection",
                "Uveitis, iritis, and other ocular inflammatory toxicities can occur; some cases can be associated with retinal detachment; various grades of visual impairment, including blindness, can occur; if uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss",
                "Do not substitute paclitaxel protein-bound with paclitaxel in combination with drug in clinical practice for metastatic TNBC outside of controlled trials",
                "Can cause fetal harm; advise females of reproductive potential of potential risk to a fetus and use of effective contraception "
            ],
            "specific": [
                {
                    "type": "Immune-related endocrinopathies",
                    "description": [
                        "Immune-related myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, or meningoencephalitis reported; permanently discontinue for any grade",
                        "Monitor for clinical signs and symptoms of meningitis or encephalitis",
                        "Monitor for symptoms of motor and sensory neuropathy",
                        "Symptomatic pancreatitis without an alternative etiology occurred in 0.1% of patients across clinical trials; pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis; monitor for signs and symptoms of acute pancreatitis",
                        "Monitor for signs and symptoms of myocarditis",
                        "Thyroid disorders may occur; thyroiditis can present with or without endocrinopathy; not reported to lead to permanent discontinuation; hypothyroidism can follow hyperthyroidism monitor thyroid function prior to and periodically during treatment; initiate hormone replacement therapy or medical management of hyperthyroidism as clinically indicated; continue therapy for hypothyroidism and interrupt for hyperthyroidism or permanently discontinue therapy based on severity",
                        "Adrenal insufficiency may occur; monitor patients for clinical signs and symptoms of adrenal insufficiency",
                        "Type 1 diabetes mellitus reported; monitor for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated; interrupt treatment based on severity",
                        "Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatic reported",
                        "Hypoparathyroidism may occur",
                        "Hypophysitis/hypopituitarism may occur; hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts; hypophysitis can cause hypopituitarism; withhold or permanently discontinue therapy depending on severity; for Grade 2 or higher hypophysitis, initiate prednisone 1-2 mg/kg/day or equivalents, followed by a taper and hormone replacement therapy as clinically indicated"
                    ]
                },
                {
                    "type": "FDA Safety Alert",
                    "description": [
                        "On 9/8/2020, FDA alerted health care professionals, oncology clinical investigators, and patients that the combination of atezolizumab and paclitaxel in previously untreated inoperable locally advanced or metastatic TNBC was ineffective",
                        "Alert was based on results from the IMpassion131 trial, a doubled-blind, multicenter, placebo-controlled trial comparing atezolizumab or placebo in combination with paclitaxel for patients with metastatic TNBC",
                        "In this trial, atezolizumab and paclitaxel did not significantly reduce the risk of cancer progression and death compared with placebo and paclitaxel in PD-L1-positive population",
                        "Increase in risk of death observed in patients treated with atezolizumab plus paclitaxel compared with placebo and paclitaxel in PD-L1-positive population; the efficacy of atezolizumab in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC has not been demonstrated",
                        "Interim overall survival results favored paclitaxel and placebo, over paclitaxel and atezolizumab in both the PD-L1-positive population and total population"
                    ]
                },
                {
                    "type": "Immune-mediated adverse reactions",
                    "description": [
                        "Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue; reactions can occur at any time after starting a PD­1/PD-L1 blocking antibody",
                        "While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies",
                        "Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies; monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions",
                        "Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment; in cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection",
                        "Institute medical management promptly, including specialty consultation as appropriate; withhold or permanently discontinue therapy depending on severity; in general, if therapy requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less",
                        "Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month; consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy"
                    ]
                },
                {
                    "type": "Complications of allogeneic HSCT",
                    "description": [
                        "Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody",
                        "Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause)",
                        "These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT",
                        "Follow patients closely for evidence of transplant-related complications and intervene promptly; consider benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT"
                    ]
                },
                {
                    "type": "Colitis",
                    "description": [
                        "Drug can cause immune-mediated colitis that can present with diarrhea, abdominal pain, and lower gastrointestinal (GI) bleeding",
                        "Cytomegalovirus (CMV) infection/ reactivation reported in patients with corticosteroid-refractory immune-mediated colitis",
                        "In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Increased triacylglycerol lipase",
            "percent": "46"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "24"
        },
        {
            "name": "Increased creatinine kinase",
            "percent": "22"
        },
        {
            "name": "Decreased phosphorus",
            "percent": "22"
        },
        {
            "name": "Hepatoxicity",
            "percent": "21"
        },
        {
            "name": "Increased ALT",
            "percent": "18"
        },
        {
            "name": "Increased AST",
            "percent": "13"
        },
        {
            "name": "Increased amylase",
            "percent": "13"
        },
        {
            "name": "Hypertension",
            "percent": "10"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "6"
        },
        {
            "name": "Decreased sodium",
            "percent": "5"
        },
        {
            "name": "Decreased potassium",
            "percent": "5"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "4.3"
        },
        {
            "name": "Increased bilirubin",
            "percent": "3.1"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Infusion",
            "percent": "2.6"
        },
        {
            "name": "related reaction",
            "percent": "1.7"
        },
        {
            "name": "Pyrexia",
            "percent": "1.3"
        },
        {
            "name": "Stomatitis",
            "percent": "1.3"
        },
        {
            "name": "Increased potassium",
            "percent": "1.3"
        },
        {
            "name": "Decreased calcium",
            "percent": "1.3"
        },
        {
            "name": "Pneumonitis",
            "percent": "1"
        },
        {
            "name": "Hyperthyroidism",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": "1"
        },
        {
            "name": "Edema",
            "percent": "0.9"
        },
        {
            "name": "Decreased albumin",
            "percent": null
        }
    ]
}